Genomics & Precision Medicine Penny Stocks

US-listed genomics and precision-medicine penny stocks priced $0.50 to $5, ranked by today's percentage change. Gene editing, gene therapy, sequencing technology, liquid biopsy, companion diagnostics, and precision-medicine platforms. Updated intraday.

Data as of 10/13/2026 6:33:06 AM · Intraday prices · 56 penny stocks in theme
#SymbolCompanySectorPriceDay ChgVolume
1PASGPassage Bio, Inc. Common StockHealthcare$4.3260+22.76%66K
2BGLCBioNexus Gene Lab Corp Common stockHealthcare$1.4100+6.20%9K
3MDXHMDxHealth SA Ordinary SharesHealthcare$0.5970+3.44%292K
4CCELCryo-Cell International Inc.Healthcare$4.4980+3.21%43K
5IBIOiBio, Inc. Common StockHealthcare$0.9020+2.20%439K
6AVXLAnavex Life SciencesHealthcare$1.4900+2.01%1.0M
7MGXMetagenomi Therapeutics, Inc. Common StockHealthcare$1.0290+2.00%146K
8CSBRChampions Oncology, Inc.Healthcare$4.9800+1.76%11K
9SERASera Prognostics, Inc. Class A Common StockHealthcare$2.0650+0.98%14K
10IRDOpus Genetics, Inc. Common StockHealthcare$4.6860+0.22%1.1M
11XCURExicure, Inc. Common StockHealthcare$1.11400.00%14K
12OABIOmniAb, Inc. Common StockHealthcare$4.7590-0.21%930K
13GNLXGenelux Corporation Common StockHealthcare$2.5400-0.39%71K
14ACRVAcrivon Therapeutics, Inc. Common StockHealthcare$1.8870-0.52%137K
15OPKOpko Health Inc.Healthcare$1.3990-0.72%896K
16GNPXGenprex, Inc. Common StockHealthcare$2.7010-0.74%265K
17OCGNOcugen, Inc. Common StockHealthcare$0.9510-0.89%3.1M
18ABEOAbeona Therapeutics Inc. Common StockHealthcare$4.8950-0.91%562K
19PRQRProQR Therapeutics N.V. Ordinary SharesHealthcare$1.6580-0.92%1.5M
20JSPRJasper Therapeutics, Inc. Common StockHealthcare$0.5580-0.93%335K
21TNYATenaya Therapeutics, Inc. Common StockHealthcare$0.5570-1.29%2.5M
22MXCTMaxCyte, Inc. Common StockHealthcare$1.0130-1.69%140K
23LGVNLongeveron Inc. Common StockHealthcare$2.4270-1.81%34K
24SEERSeer, Inc. Class A Common StockHealthcare$2.1450-1.83%101K
25IMNNImunon, Inc. Common StockHealthcare$1.0620-1.85%42K
26FHTXFoghorn Therapeutics Inc. Common StockHealthcare$1.9550-2.00%527K
27ENGNenGene Therapeutics Inc. Common StockHealthcare$1.7200-2.02%453K
28ACIUAC Immune SAHealthcare$2.4220-2.40%145K
29RCKTRocket Pharmaceuticals, Inc. Common StockHealthcare$2.5000-2.73%2.2M
30MYGNMyriad Genetics IncHealthcare$4.1850-2.78%1.1M
31BCDABioCardia, Inc. Common StockHealthcare$1.0200-2.88%78K
32CAMPCAMP4 Therapeutics Corporation Common StockHealthcare$3.7690-2.92%26K
33PHIOPhio Pharmaceuticals Corp. Common StockHealthcare$0.9800-3.37%45K
34NAUTNautilus Biotechnolgy, Inc. Common StockHealthcare$2.1940-3.56%13.2M
35CDIOCardio Diagnostics Holdings Inc. Common stockHealthcare$1.9590-3.74%61K
36PRLDPrelude Therapeutics IncorporatedHealthcare$3.7450-3.86%169K
37QTRXQuanterix Corporation Common StockHealthcare$3.1550-3.96%511K
38ALLOAllogene Therapeutics, Inc. Common StockHealthcare$1.4100-4.11%3.8M
39LABStandard BioTools Inc. Common StockHealthcare$0.6540-4.25%467K
40INOInovio Pharmaceuticals, Inc.Healthcare$1.1070-4.35%2.3M
41CBUSCibus, Inc. Class A Common StockHealthcare$1.4810-4.52%89K
42WVEWave Life Sciences Ltd. Ordinary SharesHealthcare$3.3140-5.49%1.9M
43LXEOLexeo Therapeutics, Inc. Common StockHealthcare$3.0550-5.57%876K
44EDITEditas Medicine, Inc. Common StockHealthcare$2.7600-5.86%1.2M
45SANASana Biotechnology, Inc. Common StockHealthcare$2.6300-5.91%2.3M
46IMDXInsight Molecular Diagnostics Inc. Common StockHealthcare$3.2000-6.23%212K
47BNGOBionano Genomics, Inc. Common StockHealthcare$1.3510-6.62%461K
48CABACabaletta Bio, Inc. Common StockHealthcare$1.8380-6.99%3.8M
49TSHATaysha Gene Therapies, Inc. Common StockHealthcare$4.1750-7.91%1.9M
50VYGRVoyager Therapeutics, Inc. Common StockHealthcare$2.2890-8.16%832K

How Genomics Penny Stocks Trade

Genomics at sub-$5 is a mix of gene-editing platforms (CRISPR, base/prime editing, ZFNs), gene therapy specialists, sequencing-tool makers, and diagnostics companies. Like oncology, the trading is catalyst-driven — clinical readouts, FDA actions, and competitive technology announcements move individual names sharply.

  • Editing technology approach: CRISPR-Cas9, base editing, prime editing, and ZFN platforms have different IP, safety profiles, and timelines. Don't aggregate.
  • Gene therapy reimbursement: approved gene therapies cost $1M-$3M per patient. Payer adoption shapes commercial trajectory.
  • Sequencing instrument cycles: sequencing-tool plays trade with the Illumina/Element/etc. competitive landscape.
  • FDA novel-modality posture: the agency's evolving framework for gene/cell therapies affects approval timelines.
  • IP litigation: the CRISPR patent landscape has had years of litigation. Court rulings move names that depend on specific IP positions.
  • Manufacturing scale: gene therapies require specialized manufacturing. Companies with internal capacity trade at premiums to outsourced models.
  • Rare disease focus: orphan indications get faster approvals and pricing power but smaller markets. Trade-offs to weigh.
  • Dilution profile: like other clinical-stage biotechs, sub-$5 genomics names raise capital frequently — see our dilution explainer.

See also: biotech penny stocks (broader), oncology penny stocks, penny stocks under $1.

Market themes and sectors — the full-market view, all price ranges.